<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Chronic complications of the short bowel syndrome in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Chronic complications of the short bowel syndrome in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Chronic complications of the short bowel syndrome in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John K DiBaise, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            J Thomas Lamont, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shilpa Grover, MD, MPH, AGAF
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 01, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Short bowel syndrome (SBS) is a malabsorptive state that typically occurs following extensive resection of the small intestine. It is a functional definition, implying a significant amount of malabsorption of both macronutrients and micronutrients and is not necessarily dependent on the loss of bowel or a particular length of bowel. Patients with SBS are at risk for several complications. These complications may result from the underlying disease, altered bowel anatomy and physiology, or its treatment, including the need for
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         and the use of a central venous catheter. Acute complications that can occur at any time include watery diarrhea, electrolyte disturbances, and catheter-related complications.
        </p>
        <p>
         This topic will review the chronic complications of SBS in adults. The pathophysiology and management of SBS, including small bowel transplantation, are discussed separately.
        </p>
        <p class="headingAnchor" id="H323101519">
         <span class="h1">
          ESOPHAGITIS/PEPTIC ULCER DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastric hypersecretion is common after SBS and may last 6 to 12 months postoperatively [
         <a href="#rid1">
          1
         </a>
         ]. In a minority of cases, gastric hypersecretion may lead to esophagitis and/or peptic ulcer disease and patients may present with symptoms of heartburn, regurgitation, dysphagia, or abdominal pain. (See
         <a class="medical medical_review" href="/z/d/html/4770.html" rel="external">
          "Pathophysiology of short bowel syndrome", section on 'Ileal versus jejunal adaptation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2265.html" rel="external">
          "Clinical manifestations and diagnosis of gastroesophageal reflux in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/26.html" rel="external">
          "Peptic ulcer disease: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
         Gastric hypersecretion is thought to occur as a result of the loss of inhibitory hormones produced in the proximal gut (eg, gastric inhibitory peptide and vasoactive intestinal peptide). The volume of secretions entering the small bowel increases and the pH of the secretions in the proximal gut is lowered, aggravating fluid losses and leading to peptic complications and impairment in the function of pancreatic exocrine secretions, further contributing to fat maldigestion. (See
         <a class="medical medical_review" href="/z/d/html/4770.html" rel="external">
          "Pathophysiology of short bowel syndrome", section on 'Ileal versus jejunal adaptation'
         </a>
         .)
        </p>
        <p>
         Antisecretory medications (eg, proton pump inhibitors or histamine 2-receptor antagonists) used in the early postoperative period in patients with SBS reduce gastric secretions, improve digestion and absorption, and can prevent peptic complications. In patients with gastroesophageal reflux disease or peptic ulcer disease, acid-suppressing medications are used to treat symptoms. However, acid-suppressing medications should be weaned or used at the lowest possible dose in patients with SBS as long-term use is associated with an increased risk of small intestinal bacterial overgrowth and other side effects [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4773.html" rel="external">
          "Management of short bowel syndrome in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/32.html" rel="external">
          "Antiulcer medications: Mechanism of action, pharmacology, and side effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1148337666">
         <span class="h1">
          DIARRHEA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diarrhea in patients with SBS may be multifactorial in etiology. Diarrhea can result from a reduction of absorptive surface area; decrease in intestinal transit time; humorally mediated gastric, small intestinal, and colonic hypersecretion; impairment in the function of pancreatic exocrine secretions, leading to fat maldigestion; or small intestinal bacterial overgrowth [
         <a href="#rid3">
          3
         </a>
         ]. Additionally, it is important to recognize that diarrhea may occur due to the underlying disease (eg, Crohn disease) or an acute process (eg, Clostridioides difficile infection [formerly known as
         <em>
          Clostridium difficile
         </em>
         ]).
        </p>
        <p class="headingAnchor" id="H1148337816">
         <span class="h2">
          Small intestinal bacterial overgrowth
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with small intestinal bacterial overgrowth can present with bloating, flatulence, abdominal discomfort, diarrhea, or steatorrhea. Symptoms of small intestinal bacterial overgrowth can lead to a reduction in oral intake and, in turn, delay weaning of
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/4776.html" rel="external">
          "Small intestinal bacterial overgrowth: Clinical manifestations and diagnosis", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         Bacterial overgrowth in patients with SBS results from progressive dilation of the small intestine as part of the intestinal adaptation response to resection [
         <a href="#rid4">
          4
         </a>
         ]. This limits the efficacy of peristalsis in ridding the small intestine of bacteria. Other contributing factors include the absence of an ileocecal valve to prevent reflux of bacteria into the small intestine, compromised enterocyte turnover due to suboptimal enteral nutrient stimulation, and theoretically, the use of acid-suppressive and antimotility medications. (See
         <a class="medical medical_review" href="/z/d/html/4770.html" rel="external">
          "Pathophysiology of short bowel syndrome", section on 'Ileal versus jejunal adaptation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1148338031">
         <span class="h3">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of small intestinal bacterial overgrowth in patients with SBS requires small bowel aspirate with quantitative bacterial cultures [
         <a href="#rid3">
          3
         </a>
         ]. If small bowel aspirate is not available, a presumptive diagnosis is generally made in patients with SBS and bloating, flatulence, abdominal discomfort, diarrhea, or steatorrhea. Hydrogen breath tests should not be used to diagnose small intestinal bacterial overgrowth in patients with SBS as rapid transit in the shortened bowel makes it difficult to differentiate small bowel versus colonic hydrogen production. The diagnosis of small intestinal bacterial overgrowth is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4776.html" rel="external">
          "Small intestinal bacterial overgrowth: Clinical manifestations and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1148338037">
         <span class="h3">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Small intestinal bacterial overgrowth is managed with antibiotics and dietary modification with a proportionally higher fat-containing diet to reduce the carbohydrate substrate available for bacterial metabolism [
         <a href="#rid5">
          5
         </a>
         ]. The continuous use of low-dose antibiotics in SBS may be necessary in some patients. While without supporting evidence to reduce the risk of antibiotic resistance, it is often recommended that antibiotics should be periodically rotated. Other strategies that have been suggested to be useful for controlling bacterial overgrowth include limiting the use of antisecretory and antimotility agents and intermittent bowel flushing with polyethylene glycol. Although the use of surgical bowel tapering has been reported, there are insufficient data to recommend it for management of small intestinal bacterial overgrowth in patients with SBS [
         <a href="#rid6">
          6
         </a>
         ]. The management of small intestinal bacterial overgrowth is discussed in detail, separately. (See
         <a class="medical medical_review" href="/z/d/html/4778.html" rel="external">
          "Small intestinal bacterial overgrowth: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          HEPATIC STEATOSIS AND CHOLESTASIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 15 to 40 percent of adults with SBS develop liver disease due to the use of
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         and other factors present in SBS patients with intestinal failure (ie, require parenteral fluid or nutrition support). For this reason, the term intestinal failure-associated liver disease (IFALD) is preferred over parenteral nutrition-associated liver disease (PNALD). Diagnosis includes a combination of biochemical, clinical, and in some cases, histologic findings, and is considered after excluding other causes of liver dysfunction. While steatosis is more commonly seen in adults, cholestasis occurs more commonly in children. In adults, the risk of liver disease is greatest in those with a small bowel segment &lt;50 cm, lack of colon-in-continuity, absence of oral/enteral intake, presence of intra-abdominal inflammation, recurrent central venous catheter-related sepsis, small intestinal bacterial overgrowth, and parenteral nutrition-related factors, particularly lipid or glucose overload and the type of intravenous lipid emulsion [
         <a href="#rid7">
          7
         </a>
         ]. Most patients are asymptomatic but may have elevations in hepatic aminotransferases. Severe steatosis and cholestasis can progress to end-stage liver disease. Cholestatic liver dysfunction may lead to cirrhosis and portal hypertension and is an indication for combined liver/intestine transplantation [
         <a href="#rid8">
          8,9
         </a>
         ]. Life-threatening liver disease caused by parenteral nutrition is rare, particularly in adults. However, when it occurs, it is most often due to sepsis, drug toxicity, and, possibly, bacterial overgrowth [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3625.html" rel="external">
          "Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3600.html" rel="external">
          "Management of nonalcoholic fatty liver disease in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5948.html" rel="external">
          "Intestinal failure-associated liver disease in infants"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Prevention and management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several strategies have been suggested for preventing or slowing the development of liver disease [
         <a href="#rid7">
          7,10
         </a>
         ]. These include the following (see
         <a class="medical medical_review" href="/z/d/html/5948.html" rel="external">
          "Intestinal failure-associated liver disease in infants"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adjusting
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         to provide the minimum level of total energy and macronutrients required, limiting the lipid dose to 1 g/kg/day, cycling parenteral nutrition, treating deficiencies (choline, essential fatty acids, carnitine, taurine, glutathione), and preventing and promptly treating catheter-related sepsis [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intestinal rehabilitation programs that involve aggressive use of enteral nutrition, control of small bowel bacterial overgrowth, and prevention of catheter sepsis [
         <a href="#rid12">
          12,13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4778.html" rel="external">
          "Small intestinal bacterial overgrowth: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15671.html" rel="external">
          "Routine care and maintenance of intravenous devices"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">
          Ursodeoxycholic acid
         </a>
         (UDCA) is beneficial in some chronic cholestatic liver diseases, particularly primary biliary cholangitis [
         <a href="#rid14">
          14
         </a>
         ]. Most studies of UDCA in patients with parenteral nutrition-associated cholestasis have been in children. In adults, 10 to 15 mg/kg/day administered in two to three doses seems to improve the biochemical and clinical signs and symptoms of cholestasis [
         <a href="#rid15">
          15
         </a>
         ]. However, studies with long-term follow-up are needed to determine if UDCA improves clinical outcomes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Novel intravenous lipid emulsions (eg, fish oil and combination soybean, medium chain triglyceride, olive oil and fish oil) have become available for clinical use in the US as traditional soybean lipid emulsions, which have a high content of omega-6 fatty acids, have been implicated in the pathogenesis of IFALD [
         <a href="#rid16">
          16-21
         </a>
         ]. However, while these are FDA-approved for use, their benefit in adults remains to be clearly demonstrated in clinical trials. The use of fish oil-containing emulsions in parenteral nutrition-associated cholestasis in infants does not contain essential fatty acids and is discussed in detail, separately. (See
         <a class="medical medical_review" href="/z/d/html/5948.html" rel="external">
          "Intestinal failure-associated liver disease in infants", section on 'Fish oil-based lipid emulsions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          CHOLELITHIASIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with SBS are at increased risk for cholelithiasis, particularly cholesterol stones [
         <a href="#rid22">
          22,23
         </a>
         ]. In one study that included 84 patients with SBS, asymptomatic cholelithiasis was detected in 44 percent [
         <a href="#rid22">
          22
         </a>
         ]. Risk factors for cholelithiasis include the use of
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         , resection of the terminal ileum, and an intestinal remnant &lt;120 cm [
         <a href="#rid22">
          22,24
         </a>
         ]. As the risk of complications of cholelithiasis may be higher in patients with SBS as compared with the general population, prophylactic cholecystectomy may have a role when abdominal surgery is being undertaken for other reasons [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         The pathogenesis of cholelithiasis in patients with SBS is not completely understood. At least two factors may contribute:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Altered bile composition – Interruption of the enterohepatic circulation of bile acids by ileal resection results in a reduction in hepatic bile acid secretion and an altered composition of hepatic bile, which becomes supersaturated with cholesterol.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bile stasis – Diminished enteric hormonal stimulation of gallbladder contraction may lead to biliary stasis and the formation of biliary sludge.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          ELECTROLYTE AND MICRONUTRIENT DEFICIENCIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Electrolyte and micronutrient deficiencies are uncommon in short bowel patients who are receiving
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         . However, patients with SBS are at greatest risk for nutrient deficiencies during and after the time that parenteral nutrition is being weaned and discontinued [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H423020970">
         <span class="h2">
          Screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         We measure vitamin and mineral levels semiannually in those receiving
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         , at the time of parenteral nutrition discontinuation, followed by every three months for the first year, and then at least annually based on the requirements for supplementation [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H423020990">
         <span class="h2">
          Management
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fat-soluble vitamin and essential fatty acids
         </strong>
         – In the absence of supplementation, deficiencies in fat-soluble vitamins and essential fatty acids frequently occur in patients with SBS and large doses may be required to maintain normal plasma levels. Aqueous preparations of vitamins A, D, and E should be used for supplementation. In contrast, as water-soluble vitamins are absorbed in the proximal small bowel, deficiencies in SBS patients are uncommon.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vitamin B12
         </strong>
         – Deficiency of vitamin B12 occurs in patients who have undergone resection of more than 50 to 60 cm of the terminal ileum. In patients with small intestinal bacterial overgrowth, the bacteria compete for vitamin B12 and contribute to the deficiency. Vitamin B12 deficiency is characterized by a macrocytic anemia and can lead to neurologic dysfunction (dementia or weakness, sensory ataxia, and paresthesias). Patients with SBS and vitamin B12 deficiency generally require nasal or parenteral administration, although some may respond satisfactorily to high dose oral administration. (See
         <a class="medical medical_review" href="/z/d/html/7154.html" rel="external">
          "Treatment of vitamin B12 and folate deficiencies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7154.html" rel="external">
          "Treatment of vitamin B12 and folate deficiencies", section on 'Vitamin B12'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trace elements
         </strong>
         – Supplemental zinc and occasionally copper and
         <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">
          selenium
         </a>
         may be required in the presence of excessive stool losses. Although iron is absorbed in the proximal small bowel, which remains intact in most patients with SBS, iron deficiency is one of the most common deficiencies, particularly in those patients who have limited oral intake and those who require chronic
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         as it does not contain iron due to its incompatibility with lipids and propensity to cause allergic reactions [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2585.html" rel="external">
          "Overview of dietary trace elements"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Electrolytes
         </strong>
         – Magnesium, potassium, calcium, and occasionally bicarbonate supplementation may be needed in patients with SBS who have large stool losses (eg, end-jejunostomy). Hypomagnesemia occurs as a consequence of loss of magnesium-absorbing gut, the binding of magnesium by unabsorbed fatty acids, and sodium/water depletion that increases urinary magnesium losses. Hypomagnesemia may lead to hypocalcemia as a result of impaired parathyroid hormone release [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/829.html" rel="external">
          "Hypomagnesemia: Causes of hypomagnesemia", section on 'Gastrointestinal losses'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Oral magnesium salts can be administered in doses of 12 to 24 mEq/day and do not appear to increase stomal output, particularly when taken at night when intestinal transit is at its slowest. However, higher doses are frequently needed and may be difficult to use because they worsen diarrhea. Magnesium heptogluconate is especially useful in correcting hypomagnesemia without diarrhea and is available as a liquid that can be added to oral rehydration therapy. The correction of sodium depletion is critical in treating hypomagnesemia. The oral administration of 1-alpha-hydroxycholecalciferol increases both intestinal absorption and renal absorption of magnesium [
         <a href="#rid30">
          30
         </a>
         ]. However, if moderate to severe hypomagnesemia (&lt;1 mg/dL) and/or symptoms persists, parenteral magnesium may be necessary. Of note, patients with impaired kidney function are at risk for developing hypermagnesemia when replacement is provided in large doses as magnesium is renally cleared.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H262457694">
         <span class="h1">
          METABOLIC BONE DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with SBS are at increased risk for osteomalacia, osteoporosis, osteopenia, and secondary hyperparathyroidism. Specific risk factors for metabolic bone disease in patients with SBS include the effects of the
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         , malabsorption of macro- and micronutrients (eg, vitamin D), electrolyte alterations (eg, hypocalcemia, hypomagnesemia), and chronic metabolic acidosis [
         <a href="#rid31">
          31-33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2049.html" rel="external">
          "Etiology of osteoporosis in men"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2058.html" rel="external">
          "Epidemiology and etiology of premenopausal osteoporosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1148338162">
         <span class="h2">
          Screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         An assessment of bone density, preferably with dual-energy X-ray absorptiometry, should be undertaken in all patients with SBS, regardless of the need of
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         , and should be repeated biannually. The identification of significant bone disease should lead to an assessment of levels of calcium, phosphorus, magnesium, vitamin D (25-hydroxy vitamin D), and parathyroid hormone, and for the presence of metabolic acidosis.
        </p>
        <p class="headingAnchor" id="H1148338168">
         <span class="h2">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of osteoporosis includes lifestyle measures, calcium, magnesium, and vitamin D replacement and correction of metabolic acidosis. Given the poor bioavailability of bisphosphonates, intravenous agents should be used in the setting of SBS. The diagnosis and management of osteoporosis are discussed in detail, separately. (See
         <a class="medical medical_review" href="/z/d/html/2046.html" rel="external">
          "Screening for osteoporosis in postmenopausal women and men"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          NEPHROLITHIASIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with SBS are at increased risk for calcium oxalate nephrolithiasis [
         <a href="#rid34">
          34,35
         </a>
         ]. In patients with SBS with fat malabsorption and a colon-in-continuity, calcium binds to unabsorbed fatty acids, leaving oxalate free to pass into the colon to be absorbed and then filtered by the kidney. In the kidney, oxalate binds to calcium, resulting in oxalate nephrolithiasis and progressive obstructive nephropathy. Increased colonic permeability to small molecules such as oxalate induced by nonabsorbed bile acids facilitates oxalate entry into the bloodstream. A reduction in bacterial breakdown of oxalate due to decreased
         <em>
          Oxalobacter formigenes
         </em>
         also leads to increased absorption of oxalate in patients with SBS. The diarrheal fluid losses can lead to a reduction in urine volume and, in patients with metabolic acidosis, a low urine pH and a marked decrease in citrate excretion can promote uric acid as well as calcium oxalate stone formation. (See
         <a class="medical medical_review" href="/z/d/html/7375.html" rel="external">
          "Kidney stones in adults: Epidemiology and risk factors", section on 'High urine oxalate'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Prevention and management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Similar to the management of nephrolithiasis in the general population, the maintenance of adequate urine output by increasing fluid intake (&gt;1.5 L/d if prior stones) is of paramount importance. Treatment of enteric hyperoxaluria is directed at diminishing intestinal oxalate absorption [
         <a href="#rid36">
          36,37
         </a>
         ] and consists of a low-oxalate diet, high fluid intake,
         <a class="drug drug_general" data-topicid="10225" href="/z/d/drug information/10225.html" rel="external">
          potassium citrate
         </a>
         to correct metabolic acidosis if present, and oral
         <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">
          calcium carbonate
         </a>
         (1 to 4 g/day) to bind oxalate in the intestinal lumen. A low-fat, low-oxalate diet can reduce the quantity of fatty acids and free oxalate in the colon; however, is often nutritionally inadequate in patients who have SBS. The oxalate content of foods is available at the following website:
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fregepi.bwh.harvard.edu%2Fhealth%2Fnutrition.html&amp;token=8l9XGPU3xIgBIb9kYZuyZT%2FZpeGQ23%2FxYce7e1k600912lu2OphirsULbb2Ia37UzWqsc5hdIaRTTNoNyWEk7w%3D%3D&amp;TOPIC_ID=4775" target="_blank">
          http://regepi.bwh.harvard.edu/health/nutrition.html
         </a>
         .
         <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">
          Cholestyramine
         </a>
         should be avoided as it can worsen fat malabsorption in patients with SBS. (See
         <a class="medical medical_review" href="/z/d/html/7373.html" rel="external">
          "Kidney stones in adults: Prevention of recurrent kidney stones"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          D-LACTIC ACIDOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         D-lactic acidosis is a rare neurologic syndrome characterized by altered mental status ranging from confusion to coma, slurred speech, seizures, and ataxia resulting from bacterial fermentation of unabsorbed carbohydrates. It primarily occurs in patients with an intact colon and often in the setting of underlying bacterial overgrowth. It appears to be more common in children with SBS than adults. In such patients, delivery of unabsorbed carbohydrate to the colon causes Gram-positive anaerobic bacteria to produce D-lactate (rather than the L-lactate that is produced by normal metabolic processes) [
         <a href="#rid38">
          38
         </a>
         ]. The pathogenesis, clinical manifestations, diagnosis, and management of D-lactic acidosis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2303.html" rel="external">
          "D-lactic acidosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1148337651">
         <span class="h1">
          CATHETER-RELATED COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients who require long-term
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         experience complications related to the indwelling central venous catheter, which may include blood stream infections and mechanical issues such as catheter breakage and occlusion. The prevention, diagnosis, and management of catheter-related complications are discussed in detail, separately. (See
         <a class="medical medical_review" href="/z/d/html/1626.html" rel="external">
          "Nutrition support in intubated critically ill adult patients: Parenteral nutrition", section on 'Complications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3813.html" rel="external">
          "Intravascular non-hemodialysis catheter-related infection: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3814.html" rel="external">
          "Intravascular non-hemodialysis catheter-related infection: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13982.html" rel="external">
          "Lock therapy for treatment and prevention of intravascular non-hemodialysis catheter-related infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15671.html" rel="external">
          "Routine care and maintenance of intravenous devices"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1273277892">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116514.html" rel="external">
          "Society guideline links: Short bowel syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic complications of short bowel syndrome (SBS) may result from the underlying disease, altered bowel anatomy and physiology, or its treatment, including the need for
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         and the use of a central venous catheter. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastric hypersecretion is common after SBS and may last 6 to 12 months postoperatively. In a minority of cases, gastric hypersecretion may lead to esophagitis and/or peptic ulcer disease and patients may present with symptoms of heartburn, regurgitation, and dysphagia or abdominal pain. Acid-suppressing medications should be used at the lowest possible dose in patients with SBS as long-term use is associated with an increased risk of small intestinal bacterial overgrowth and other side effects. (See
         <a class="local">
          'Esophagitis/peptic ulcer disease'
         </a>
         above and
         <a class="local">
          'Small intestinal bacterial overgrowth'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with SBS who require long-term
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         are at risk for the development of liver disease and cholelithiasis. Strategies for prevention of liver disease include adjusting parenteral nutrition to provide the minimum level of total energy and macronutrients required, (possibly) using novel intravenous lipid emulsions instead of soybean-based, cycling parenteral nutrition, aggressive use of enteral nutrition, treating small intestinal bacterial overgrowth, and preventing and promptly treating catheter-related sepsis. (See
         <a class="local">
          'Hepatic steatosis and cholestasis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diarrhea can result from a reduction of absorptive surface area; decrease in intestinal transit time; humorally mediated gastric, small intestinal, and colonic hypersecretion; impairment in the function of pancreatic exocrine secretions, leading to fat maldigestion; or small intestinal bacterial overgrowth. The diagnosis of small intestinal bacterial overgrowth in patients with SBS is made with small bowel aspirate with quantitative bacterial cultures. Small intestinal bacterial overgrowth is managed with antibiotics and dietary manipulation to reduce the carbohydrate substrate available for bacterial metabolism. (See
         <a class="local">
          'Diarrhea'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electrolyte and micronutrient deficiencies are uncommon in short bowel patients who are receiving
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         . However, patients with SBS are at greatest risk for nutrient deficiencies during and after the time that parenteral nutrition is being weaned and discontinued. We measure vitamin and mineral levels semiannually in those receiving parenteral nutrition, at the time of parenteral nutrition discontinuation, followed by every three months for the first year, and then at least annually based on the requirements for supplementation. (See
         <a class="local">
          'Electrolyte and micronutrient deficiencies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with SBS are at risk for metabolic bone disease and can develop osteomalacia, osteoporosis, osteopenia, and secondary hyperparathyroidism. Specific risk factors for metabolic bone disease in patients with SBS include the effects of the
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         , malabsorption of macro- and micronutrients (eg, vitamin D), electrolyte alterations (eg, hypocalcemia, hypomagnesemia), and chronic metabolic acidosis. We therefore screen for bone disease in patients with SBS with dual-energy X-ray absorptiometry at baseline and then every two years. (See
         <a class="local">
          'Metabolic bone disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with SBS and a colon–in-continuity with intestinal contents are at increased risk for oxaluria and nephrolithiasis. The management of patients with enteric hyperoxaluria includes a low-oxalate diet, high fluid intake,
         <a class="drug drug_general" data-topicid="10225" href="/z/d/drug information/10225.html" rel="external">
          potassium citrate
         </a>
         to correct metabolic acidosis if present, and oral
         <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">
          calcium carbonate
         </a>
         to bind oxalate in the intestinal lumen. (See
         <a class="local">
          'Nephrolithiasis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         D-lactic acidosis is a rare neurologic syndrome characterized by altered mental status ranging from confusion to coma, slurred speech, seizures, and ataxia resulting from bacterial fermentation of unabsorbed carbohydrates. It primarily occurs in patients with an intact colon and often in the setting of underlying bacterial overgrowth. (See
         <a class="local">
          'D-lactic acidosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1802719">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate acknowledge Jon Vanderhoof, MD, and Rosemary Pauley-Hunter, NP-C, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Williams NS, Evans P, King RF. Gastric acid secretion and gastrin production in the short bowel syndrome. Gut 1985; 26:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortot A, Fleming CR, Malagelada JR. Improved nutrient absorption after cimetidine in short-bowel syndrome with gastric hypersecretion. N Engl J Med 1979; 300:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dibaise JK, Young RJ, Vanderhoof JA. Enteric microbial flora, bacterial overgrowth, and short-bowel syndrome. Clin Gastroenterol Hepatol 2006; 4:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ziegler TR, Cole CR. Small bowel bacterial overgrowth in adults: a potential contributor to intestinal failure. Curr Gastroenterol Rep 2007; 9:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Attar A, Flourié B, Rambaud JC, et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999; 117:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanderhoof JA, Young RJ, Murray N, Kaufman SS. Treatment strategies for small bowel bacterial overgrowth in short bowel syndrome. J Pediatr Gastroenterol Nutr 1998; 27:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly DA. Preventing parenteral nutrition liver disease. Early Hum Dev 2010; 86:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanderhoof JA, Langnas AN. Short-bowel syndrome in children and adults. Gastroenterology 1997; 113:1767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carrion AF, Bhamidimarri KR. Liver transplant for cholestatic liver diseases. Clin Liver Dis 2013; 17:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pironi L, Sasdelli AS. Intestinal Failure-Associated Liver Disease. Clin Liver Dis 2019; 23:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cavicchi M, Beau P, Crenn P, et al. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med 2000; 132:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torres C, Sudan D, Vanderhoof J, et al. Role of an intestinal rehabilitation program in the treatment of advanced intestinal failure. J Pediatr Gastroenterol Nutr 2007; 45:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moon J, Iyer K. Intestinal rehabilitation and transplantation for intestinal failure. Mt Sinai J Med 2012; 79:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudic JS, Poropat G, Krstic MN, et al. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2012; 12:CD000551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           San Luis VA, Btaiche IF. Ursodiol in patients with parenteral nutrition-associated cholestasis. Ann Pharmacother 2007; 41:1867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pironi L, Agostini F, Guidetti M. Intravenous lipids in home parenteral nutrition. World Rev Nutr Diet 2015; 112:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nandivada P, Cowan E, Carlson SJ, et al. Mechanisms for the effects of fish oil lipid emulsions in the management of parenteral nutrition-associated liver disease. Prostaglandins Leukot Essent Fatty Acids 2013; 89:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mercer DF, Hobson BD, Fischer RT, et al. Hepatic fibrosis persists and progresses despite biochemical improvement in children treated with intravenous fish oil emulsion. J Pediatr Gastroenterol Nutr 2013; 56:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puder M, Valim C, Meisel JA, et al. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg 2009; 250:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Meijer VE, Gura KM, Le HD, et al. Fish oil-based lipid emulsions prevent and reverse parenteral nutrition-associated liver disease: the Boston experience. JPEN J Parenter Enteral Nutr 2009; 33:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burns DL, Gill BM. Reversal of parenteral nutrition-associated liver disease with a fish oil-based lipid emulsion (Omegaven) in an adult dependent on home parenteral nutrition. JPEN J Parenter Enteral Nutr 2013; 37:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nightingale JM, Lennard-Jones JE, Gertner DJ, et al. Colonic preservation reduces need for parenteral therapy, increases incidence of renal stones, but does not change high prevalence of gall stones in patients with a short bowel. Gut 1992; 33:1493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gao X, Zhang L, Wang S, et al. Prevalence, Risk Factors, and Complications of Cholelithiasis in Adults With Short Bowel Syndrome: A Longitudinal Cohort Study. Front Nutr 2021; 8:762240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dray X, Joly F, Reijasse D, et al. Incidence, risk factors, and complications of cholelithiasis in patients with home parenteral nutrition. J Am Coll Surg 2007; 204:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson JS, Mercer DF, Vargas LM, et al. Prophylactic cholecystectomy in short bowel syndrome: Is it being utilized? Am J Surg 2018; 216:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braga CB, Vannucchi H, Freire CM, et al. Serum vitamins in adult patients with short bowel syndrome receiving intermittent parenteral nutrition. JPEN J Parenter Enteral Nutr 2011; 35:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiBaise JK, Matarese LE, Messing B, Steiger E. Strategies for parenteral nutrition weaning in adult patients with short bowel syndrome. J Clin Gastroenterol 2006; 40 Suppl 2:S94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hwa YL, Rashtak S, Kelly DG, Murray JA. Iron Deficiency in Long-Term Parenteral Nutrition Therapy. JPEN J Parenter Enteral Nutr 2016; 40:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anast CS, Winnacker JL, Forte LR, Burns TW. Impaired release of parathyroid hormone in magnesium deficiency. J Clin Endocrinol Metab 1976; 42:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukumoto S, Matsumoto T, Tanaka Y, et al. Renal magnesium wasting in a patient with short bowel syndrome with magnesium deficiency: effect of 1 alpha-hydroxyvitamin D3 treatment. J Clin Endocrinol Metab 1987; 65:1301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Acca M, Ragno A, Francucci CM, D'Erasmo E. Metabolic bone diseases during long-term total parenteral nutrition. J Endocrinol Invest 2007; 30:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson E, Vu L, Matarese LE. Bacteria, Bones, and Stones: Managing Complications of Short Bowel Syndrome. Nutr Clin Pract 2018; 33:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nygaard L, Skallerup A, Olesen SS, et al. Osteoporosis in patients with intestinal insufficiency and intestinal failure: Prevalence and clinical risk factors. Clin Nutr 2018; 37:1654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang J, Sun H, Wan S, et al. Risk Factors for Nephrolithiasis in Adults with Short Bowel Syndrome. Ann Nutr Metab 2019; 75:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudziński M, Ławiński M, Gradowski Ł, et al. Kidney stones are common in patients with short-bowel syndrome receiving long-term parenteral nutrition: A predictive model for urolithiasis. JPEN J Parenter Enteral Nutr 2022; 46:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nightingale JM. Hepatobiliary, renal and bone complications of intestinal failure. Best Pract Res Clin Gastroenterol 2003; 17:907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asplin JR. The management of patients with enteric hyperoxaluria. Urolithiasis 2016; 44:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petersen C. D-lactic acidosis. Nutr Clin Pract 2005; 20:634.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4775 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4029719" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Gastric acid secretion and gastrin production in the short bowel syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31563" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Improved nutrient absorption after cimetidine in short-bowel syndrome with gastric hypersecretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16431299" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Enteric microbial flora, bacterial overgrowth, and short-bowel syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18377796" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Small bowel bacterial overgrowth in adults: a potential contributor to intestinal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10500060" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9702645" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Treatment strategies for small bowel bacterial overgrowth in short bowel syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20923719" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Preventing parenteral nutrition liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9352883" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Short-bowel syndrome in children and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23540507" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Liver transplant for cholestatic liver diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30947877" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Intestinal Failure-Associated Liver Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10744588" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17667717" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Role of an intestinal rehabilitation program in the treatment of advanced intestinal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22499496" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Intestinal rehabilitation and transplantation for intestinal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23235576" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Ursodeoxycholic acid for primary biliary cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17911205" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Ursodiol in patients with parenteral nutrition-associated cholestasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25471810" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Intravenous lipids in home parenteral nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23602846" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Mechanisms for the effects of fish oil lipid emulsions in the management of parenteral nutrition-associated liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23201707" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Hepatic fibrosis persists and progresses despite biochemical improvement in children treated with intravenous fish oil emulsion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19661785" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19571170" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Fish oil-based lipid emulsions prevent and reverse parenteral nutrition-associated liver disease: the Boston experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22683685" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Reversal of parenteral nutrition-associated liver disease with a fish oil-based lipid emulsion (Omegaven) in an adult dependent on home parenteral nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1452074" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Colonic preservation reduces need for parenteral therapy, increases incidence of renal stones, but does not change high prevalence of gall stones in patients with a short bowel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34912839" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Prevalence, Risk Factors, and Complications of Cholelithiasis in Adults With Short Bowel Syndrome: A Longitudinal Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17189108" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Incidence, risk factors, and complications of cholelithiasis in patients with home parenteral nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29753389" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Prophylactic cholecystectomy in short bowel syndrome: Is it being utilized?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21628608" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Serum vitamins in adult patients with short bowel syndrome receiving intermittent parenteral nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16770168" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Strategies for parenteral nutrition weaning in adult patients with short bowel syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25972429" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Iron Deficiency in Long-Term Parenteral Nutrition Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/177448" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Impaired release of parathyroid hormone in magnesium deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3680484" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Renal magnesium wasting in a patient with short bowel syndrome with magnesium deficiency: effect of 1 alpha-hydroxyvitamin D3 treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17721075" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Metabolic bone diseases during long-term total parenteral nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29926935" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Bacteria, Bones, and Stones: Managing Complications of Short Bowel Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28823627" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Osteoporosis in patients with intestinal insufficiency and intestinal failure: Prevalence and clinical risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31434099" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Risk Factors for Nephrolithiasis in Adults with Short Bowel Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33938015" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Kidney stones are common in patients with short-bowel syndrome receiving long-term parenteral nutrition: A predictive model for urolithiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14642857" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Hepatobiliary, renal and bone complications of intestinal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26645872" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The management of patients with enteric hyperoxaluria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16306301" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : D-lactic acidosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
